The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAccrol Gp Regulatory News (ACRL)

Share Price Information for Accrol Gp (ACRL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.20
Bid: 38.00
Ask: 38.20
Change: 0.00 (0.00%)
Spread: 0.20 (0.526%)
Open: 38.00
High: 38.20
Low: 37.70
Prev. Close: 38.20
ACRL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

8 Jan 2019 07:00

RNS Number : 4372M
Accrol Group Holdings PLC
08 January 2019
 

 

 

8 January 2019

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

Accrol Group Holdings plc

("Accrol Group" or the "Group")

AIM: ACRL

 

Trading Update

Accrol Group announces the following trading update, ahead of its Half Year results for the six months ended 30 October 2018 ("HY1 19"), which will be issued on 22 January 2019.

 

The Final Results for the period ended 30 April 2018, announced on 26 September 2018, stated that, whilst the Group was currently trading in line with expectations, performance in the full year to 30 April 2019 ("FY19") remained sensitive to external macro-economic variables, namely foreign exchange volatility and increasingly high paper costs.

 

Whilst the Group has been transformed operationally in 2018, addressing internal cost issues and customer margins to mitigate the significant impact of adverse headwinds, the continued weakening of Sterling against USD since September 2018 and increasing tissue prices have impacted profitability considerably. The negative impact of rising input costs and foreign exchange on the Group's profitability in H1 FY19 amounted to c.£5m. Should the current USD exchange rate and high tissue prices prevail, the Board estimates a further impact on input costs in H2 FY19 of c.£3.5m. 

 

Given macro-economic headwinds potentially contributing a total of c£8.5m additional costs in FY19 and despite the mitigating effect of the operational improvements and sales price increases implemented, the Board now expects that Adjusted EBITDA in FY19 will be c.£1m*. In terms of the overall turnaround plan itself, this is expected to result in up to £8.0m of exceptional costs in the business during FY19.

 

On a positive note, the fundamentals of the business are now stronger. The operational restructuring conducted during the year is delivering like-for-like sales at record levels (excluding discontinued Away From Home revenue). Given this growth, the directors believe that Group revenue in FY19 will increase by c.8%, broadly in line with market forecasts to c.£126m (FY18: like-for-like £116m), compared with overall UK market growth of c.8%. This market is estimated to be worth in the region of £1.5bn with established household-name brand sales declining at c.6% per annum.

 

The Directors remain confident of delivering further revenue growth whilst continuing to exit low margin work as shareholder returns are driven back to acceptable levels. Looking forward, the Group's FY20 results will include the full annualised benefit of the structural cost savings achieved in FY19, meaning it is well placed to achieve the level of monthly margins from the start of FY20 that it had hoped to achieve by the end of calendar 2018 (assuming today's levels of currency rates and input costs).

 

Net debt as at 31 October 2018 was reduced to £22.6m and management expect FY19 year-end net debt to be no more than £30.0m (FY18: £33.8m), which is a result of improved working capital management.

 

The reduction in the expected Adjusted EBITDA outcome for the Group in FY19 falls within existing banking covenants and the Group's bank remains fully supportive.

 

Gareth Jenkins, Chief Executive Officer of Accrol Group, said: 

 

"Whilst the ongoing macro headwinds encountered by the UK tissue converter industry as a whole in FY19 to date are beyond our control, we are building a more robust business which is increasingly resilient and agile under adverse macro conditions. We are confident that we can create a solid business which delivers acceptable levels of return even under difficult macro conditions and additional upside for shareholders given fair winds. The strategic plan for the Group remains on track, operationally, and the directors firmly believe Accrol Group will exit FY19 in a significantly stronger operational position."

 

* Current market forecast FY19 Adjusted EBITDA of £4.6m

 

For further information, please contact:

 

 

 

Accrol Group Holdings plc

 

Dan Wright, Executive Chairman

Tel: +44 (0) 1254 278 844

Gareth Jenkins, Chief Executive Officer

 

Steve Townsley, Chief Financial Officer

 

 

 

Zeus Capital Limited (Nominated Adviser & Broker) 

 

Dan Bate / Andrew Jones

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 203 829 5000

Belvedere Communications Limited

 

Cat Valentine (cvalentine@belvederepr.com)

Tel: +44 (0) 7715 769 078

Keeley Clarke (kclarke@belvederepr.com)

Tel: +44 (0) 7967 816 525

Llew Angus (langus@belvederpr.com)

Tel: +44 (0)7407 023 147

 

Notes to Editors

 

Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues, as well as other tissue products, to major discounters and grocery retailers throughout the UK. 

 

Accrol operates from three sites:

 

· A manufacturing, storage and distribution facility in Blackburn;

· A facial tissue plant, also in Blackburn; and

· A manufacturing, storage and distribution facility in Leyland.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTCKODBBBKBQDK
Date   Source Headline
26th Mar 202411:51 amPRNForm 8.3 - Accrol Group Holdings PLC
26th Mar 202410:02 amPRNForm 8.3 - Accrol Group Holdings plc
26th Mar 20249:17 amGNWForm 8.5 (EPT/RI) - Accrol Group Holdings Plc
25th Mar 20245:09 pmPRNForm 8.3 - Accrol Group Holdings PLC
25th Mar 20245:03 pmPRNForm 8.3 - Accrol Group Holdings Plc
25th Mar 20243:08 pmRNSForm 8.3 - ACCROL GROUP HOLDINGS PLC
25th Mar 20242:31 pmRNSForm 8.3 - Accrol Group Holdings
25th Mar 20242:19 pmRNSForm 8.3 - Accrol Group Holdings Plc
25th Mar 20241:33 pmPRNForm 8.3 - Accrol Group Holdings plc
25th Mar 202411:52 amRNSForm 8.3 - Accrol Group Holdings PLC
25th Mar 202411:00 amPRNForm 8.3 - Accrol Group Holdings plc
25th Mar 202410:51 amRNSForm 8 (DD) - Accrol Group Holdings PLC
25th Mar 202410:24 amRNSForm 8.3 - Accrol Group Holdings PLC
25th Mar 20247:59 amGNWForm 8.5 (EPT/RI) - Accrol Group Holdings Plc
22nd Mar 20241:24 pmPRNForm 8.3 - Accrol Group Holdings plc
22nd Mar 202412:28 pmRNSForm 8.3 -Accrol Group Holdings PLC
22nd Mar 20248:17 amRNSForm 8.3 - Accrol Group Holdings plc
22nd Mar 20247:00 amRNSRecommended Cash Offer
1st Mar 20243:52 pmRNSTR-1
8th Feb 20247:00 amRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSTR-1
30th Jan 20247:00 amRNSHalf Year Results
26th Jan 20247:00 amRNSNotice of Results and Investor Webinar
19th Jan 20247:00 amRNSTR-1
18th Jan 20247:00 amRNSAcquisition of Severn Delta Limited
22nd Nov 20237:00 amRNSHalf Year Trading Update
24th Oct 20232:37 pmRNSResult of AGM
18th Oct 202311:52 amRNSTR-1
18th Oct 202311:49 amRNSTR-1
17th Oct 20235:40 pmRNSTR-1
28th Sep 20239:47 amRNSNotice of AGM and Posting of Annual Report 2023
26th Sep 20237:00 amRNSFinal Results 2023
22nd Sep 20237:00 amRNSNotice of Results and Online Presentations
30th Aug 20231:20 pmRNSTR-1
22nd Aug 20237:00 amRNSDirector Dealings
18th Jul 20234:02 pmRNSTR-1
9th Jun 202311:43 amRNSTR-1
16th May 20237:00 amRNSTrading Update
2nd May 20237:00 amRNSBoard Changes
18th Apr 20234:40 pmRNSTR-1
27th Mar 20233:22 pmRNSTR-1
24th Mar 20231:38 pmRNSTR-1
7th Mar 20237:00 amRNSAppointment of Joint Broker
1st Mar 20237:00 amRNSLicensing Agreement with Unilever
27th Jan 20231:27 pmRNSTR-1
24th Jan 20237:00 amRNSHalf Year Results
24th Jan 20237:00 amRNSStrategic Review Outcomes
11th Jan 20237:00 amRNSNotice: Results, Strategic Review & Presentations
20th Dec 20227:00 amRNSDirector Dealing
28th Nov 20221:36 pmRNSLaunch of second ESG Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.